NLRP3 and diabetic retinopathy: In addition, in the retina, glibenclamide anti-edematous effects could result from the inhibition of the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome and related neuroinflammation [43], known to be involved in diabetic retinopathy mechanisms [44,45,46].